BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2510135)

  • 1. The effects of encainide versus diltiazem on the oxidative metabolic pathways of antipyrine.
    Bottorff MB; Lalonde RL; Kazierad DJ; Hoon TJ; Tsiu SJ; Mirvis DM
    Pharmacotherapy; 1989; 9(5):315-21. PubMed ID: 2510135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of diltiazem on hepatic drug oxidation assessed by antipyrine and trimethadione.
    Ohashi K; Sakamoto K; Sudo T; Tateishi T; Harada K; Fujimura A; Ebihara A; Tanaka E
    J Clin Pharmacol; 1991 Dec; 31(12):1132-6. PubMed ID: 1761736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
    Abernethy DR; Egan JM; Dickinson TH; Carrum G
    J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of encainide on in vivo drug metabolism in the rat.
    Svensson CK; Knowlton PW
    Res Commun Chem Pathol Pharmacol; 1987 May; 56(2):285-8. PubMed ID: 3110886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.
    Carrum G; Egan JM; Abernethy DR
    Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of diltiazem on the disposition of encainide and its active metabolites.
    Kazierad DJ; Lalonde RL; Hoon TJ; Mirvis DM; Bottorff MB
    Clin Pharmacol Ther; 1989 Dec; 46(6):668-73. PubMed ID: 2513160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
    Sakai H; Kobayashi S; Hamada K; Iida S; Akita H; Tanaka E; Uchida E; Yasuhara H
    Br J Clin Pharmacol; 1991 Mar; 31(3):353-5. PubMed ID: 2054276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
    Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
    Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy.
    Bauer LA; Stenwall M; Horn JR; Davis R; Opheim K; Greene L
    Clin Pharmacol Ther; 1986 Aug; 40(2):239-42. PubMed ID: 3731687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats.
    Anadón A; Martinez-Larrañaga MR; Fernandez MC; Diaz MJ; Bringas P
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2148-51. PubMed ID: 2073104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quinidine does not alter antipyrine metabolism.
    Bowles SK; Cardozo L; Edwards DJ
    J Clin Pharmacol; 1990 Mar; 30(3):267-71. PubMed ID: 2312782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of deltamethrin on antipyrine pharmacokinetics and metabolism in rat.
    Anadón A; Martinez-Larrañaga MR; Díaz MJ; Bringas P; Fernandez MC
    Arch Toxicol; 1991; 65(2):156-9. PubMed ID: 2059156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of encainide in patients with cirrhosis.
    Wensing G; Mönig H; Ohnhaus EE; Hoensch HP
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances.
    Rocci ML; Vlasses PH; Lener ME; Fruncillo RA; Sirgo MA
    J Clin Pharmacol; 1989 Oct; 29(10):891-5. PubMed ID: 2592580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of chloroquine and primaquine on antipyrine metabolism.
    Back DJ; Purba HS; Park BK; Ward SA; Orme ML
    Br J Clin Pharmacol; 1983 Nov; 16(5):497-502. PubMed ID: 6639836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metronidazole and antipyrine metabolism in the rat: clearance determination from one saliva sample.
    Loft S; Nielsen AJ; Borg BE; Poulsen HE
    Xenobiotica; 1991 Jan; 21(1):33-46. PubMed ID: 2003365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
    Adedoyin A; Aarons L; Houston JB
    Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.
    Borcherding SM; Bastian TL; Self TH; Abou-Shala N; LeDuc BW; Lalonde RL
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1553-8. PubMed ID: 1510454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.